Skip to main content

From the Helm: CSL’s David Lamont on the biotech giant’s bright future

Jessica Amir
February 20, 2020

In the latest instalment of Bell Direct’s From the Helm series, Jess has a chat with CSL’s CFO David Lamont.

David gives the inside scoop on CSL, the market leader in the blood plasma and vaccine market. Additionally, he explains CSL’s own products, programmes and partnerships, and the steps taken by the medical giant to tackle coronavirus.

Plus, he sheds some light on the unique situation the broader pharmaceuticals industry finds itself in when it comes to new competition, as well as CSL’s future proofing strategy.

Weekly Wrap 13 October

Grady Wulff
October 13, 2023

Morning Bell 13 October

Sam Kanaan
October 13, 2023

Morning Bell 12 October

Grady Wulff
October 12, 2023

Morning Bell 11 October

Grady Wulff
October 11, 2023

Morning Bell 10 October

Sam Kanaan
October 10, 2023

Morning Bell 9 October

Grady Wulff
October 9, 2023

Weekly Wrap 6 October

Grady Wulff
October 6, 2023

Morning Bell 6 October

Sam Kanaan
October 6, 2023

Morning Bell 5 October

Grady Wulff
October 5, 2023

Morning Bell 4 October

Grady Wulff
October 4, 2023

Morning Bell 3 October

Sam Kanaan
October 3, 2023

Morning Bell 2 October

Grady Wulff
October 2, 2023